

# NCI SBIR AND YOUR STATE:

## TEXAS



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$37.5 million** in funding across **31 Phase II SBIR/STTR grants** to small businesses in Texas. The following economic impact estimates quantify the program's contributions to the state's economy:



**\$251.5M**

**IN TOTAL DIRECT SALES**



**\$1.4B**

**IN TOTAL ECONOMIC IMPACT**



**5.3K**

**JOBS CREATED**



**\$44.7M**

**IN STATE & LOCAL TAXES COLLECTED**



**19**

**COMPANIES WITH SALES**

*\*These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Texas: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$106.2M in funding across all grants to oncology-focused small businesses in the state.*

### Success stories include: **BIOTEX, INC.**

Biotex used SBIR funding to develop Visualase™, a non-invasive thermal ablation system. The technology was spun out into Visualase, Inc. after receiving FDA approval in 2007. In 2014, Medtronic acquired Visualase for up to \$105 million.

### **TRANSLITE, LLC**

UT spinout and STTR awardee Translite used its funding to advance the R&D for the Nevoscope technology that enabled the DermLite™ polarized dermatoscope, which over 50% of dermatologists use to screen for skin cancer, and Veinlite™, a vein access tool that medical professionals in over 70 countries rely on for one-stick success to screen millions of patients annually.

**The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to [ncisbir@mail.nih.gov](mailto:ncisbir@mail.nih.gov).**